Loading...
XLON
BXP
Market cap293mUSD
Jul 09, Last price  
49.00GBP
1D
0.00%
Jan 2017
-3.75%
IPO
99.70%
Name

Beximco Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XLON:BXP chart
P/E
6.19
P/S
0.81
EPS
13.07
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
14.24%
Revenues
44.39b
+13.05%
3,326,972,7173,702,289,1383,596,989,5834,010,143,0564,868,245,7826,490,813,7427,890,181,3219,289,115,28410,490,699,09411,206,885,67712,965,506,87315,508,776,97217,716,716,85522,816,629,79525,611,947,65529,493,573,86934,669,172,05239,266,662,00044,391,604,000
Net income
5.83b
+26.34%
489,230,534470,691,818353,013,003545,344,689624,794,4431,051,732,8251,198,424,9921,319,389,3281,404,762,7801,528,297,5731,954,284,5162,226,695,1242,536,543,9483,033,402,3333,514,687,3015,127,693,7115,123,136,7124,614,066,0005,829,529,000
CFO
8.36b
+37.47%
311,494,2431,079,631,622340,671,788880,778,163520,885,0171,198,514,4541,246,031,9171,857,380,0702,130,330,7582,215,980,4022,112,852,5982,633,964,9861,819,113,9232,959,916,9045,542,487,2216,023,263,9555,214,176,0006,084,787,0008,364,466,317
Dividend
Nov 22, 20243.349 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The firm’s extensive product line addresses a wide range of therapeutic areas, including treatments for allergic disorders, pain and fever, various infections (antibacterial and antiviral), cardiovascular conditions, central nervous system ailments, respiratory illnesses, endocrine disorders, diabetes, gastrointestinal problems, hormonal therapies, oncology, musculoskeletal issues, and skin conditions. Its offerings also encompass eye care products, vitamin and mineral supplements, and intravenous fluids. These medications are supplied in a comprehensive array of dosage forms, such as solids, liquids, creams, ointments, suppositories, metered-dose and dry powder inhalers, nasal sprays, sterile injectables (including lyophilized forms), and large volume intravenous fluids. Beyond its own diverse portfolio, Beximco Pharmaceuticals provides contract manufacturing services to other companies and actively exports its products internationally.
IPO date
Oct 21, 2005
Employees
5,500
Domiciled in
BD
Incorporated in
BD

Valuation

Title
BDT in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT